A Study of SKB264 Versus Investigator ' s Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Conditions: Triple Negative Breast Cancer Interventions: Drug: SKB264; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Capecitabine; Drug: Eribulin; Drug: Carboplatin Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials